Manufacture of recombinant polyclonal antibodies
- 20 February 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Biotechnology Letters
- Vol. 29 (6), 845-852
- https://doi.org/10.1007/s10529-007-9331-8
Abstract
Polyclonal antibody therapy in the form of hyper-immune serum has for more than a century been used for treatment of many infectious diseases. However, with the emergence of first antibiotics and later recombinant monoclonal antibody therapy, the use of hyper-immune serum has declined. The main reason for this is that methods for consistent manufacturing of safe hyper immune immunoglobulin products have been lacking. In contrast, manufacturing processes of recombinant monoclonal antibodies follow a well established schedule and it appears obvious to use similar methods to produce recombinant polyclonal products. However, the methods for monoclonal antibody manufacturing are, for several reasons, not directly applicable to generation and manufacture of polyclonal recombinant antibodies. A new production strategy based on recombinant mammalian producer cells has recently been developed to support consistent generation of recombinant polyclonal antibodies for therapeutic use. This review describes aspects of this novel technology with emphasis on the generation, production and characterization procedures employed, and provides comparison with alternative polyclonal and monoclonal antibody manufacturing strategies.Keywords
This publication has 18 references indexed in Scilit:
- Safety and efficacy of affinity-purified, anti–tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis*Critical Care Medicine, 2006
- Production of target‐specific recombinant human polyclonal antibodies in mammalian cellsBiotechnology & Bioengineering, 2006
- Monoclonal antibody successes in the clinicNature Biotechnology, 2005
- Recombinant polyclonal antibodies for cancer therapyJournal of Cellular Biochemistry, 2005
- Production of recombinant protein therapeutics in cultivated mammalian cellsNature Biotechnology, 2004
- Passive antibody therapy for infectious diseasesNature Reviews Microbiology, 2004
- Stability of protein production from recombinant mammalian cellsBiotechnology & Bioengineering, 2003
- Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibodyProceedings of the National Academy of Sciences of the United States of America, 2002
- Return to the Past: The Case for Antibody-Based Therapies in Infectious DiseasesClinical Infectious Diseases, 1995
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975